Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
- Conditions
- Colorectal Cancer
- Interventions
- Registration Number
- NCT01442935
- Lead Sponsor
- UNICANCER
- Brief Summary
The main objective is to compare resection rates (R0 or R1) for hepatic metastases in the experimental arm (tri chemotherapy plus targeted therapy) versus the control arm (bi chemotherapy plus targeted therapy); in both arms the targeted therapy is selected according to K-Ras status of the patient's tumor.
The secondary objectives are to evaluate the objective response rate (CR and PR) after 4 cycles of treatment, according the RECIST V1.1 evaluation scale.
* the rate of complete remission (CR) at 6 months after the last study treatment (hepatic surgery or last chemotherapy cycle).
* the specific rates of resection R0, R1, R2.
* the complete pathological response Rate,
* the relapse-free survival rate in (R0 or R1) resected patients,
* the response duration in non-resected patients,
* the toxicity according to CTC AE V4 scale except for the neurotoxicity that will be evaluated with the Levi scale,
* the post operative complications using the DINDO classification,
* the progression-free survival (PFS) and overall survival (OS).
The objectives of the biological study are:
* to evaluate tumor-related predictive factors such as somatic mutations (KRAS, BRAF, TP53) and genetic amplification related factors (EGFR),
* to evaluate patient-related predictive factors in connection with genetic polymorphisms (Fc gamma and VEGF receptors),
* to evaluate ADCC activity via immunohistochemistry in order to analyze the lympho free and progression-free survival,
* to study circulating of tumor cells as prognostic factor for metastatic colorectal cancer, non- resectable at presentation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 256
- Histologically proven colorectal adenocarcinoma,
- Primary tumor of the colon or rectum, resectable or resected at least 3 weeks before randomization or 4 weeks before the beginning of the study treatment,
- Metastatic disease with synchronous or metachronous (> 3 months after diagnosis of the primary tumor) hepatic metastasis,
- Non-resectable (with respect to curative intent) hepatic metastasis at presentation. This criterion must be validated by both a surgeon and a radiologist during the RCP (Multidisciplinary cancer case presentation committee) patient's evaluation meeting (either technically non-resectable metastases (absolute contraindication): i.e. impossibility to resect all metastases in a single operation while preserving at least 30% of healthy liver tissues and/or impossibility to preserve the portal vein and hepatic artery homolateral to the liver or a portal pedicle, or due to oncological non-resectability (relative contraindication): presence of > 5 nodules and bilateral invasion),
- Hepatic metastases, without spread to other sites except in case of ≤ 3 resectable pulmonary metastases of diameter < 2 cm, detected by thoracic scanner,
- K-Ras status determined before randomization,
- Measurable disease according to the RECIST V1.1 criteria,
- No prior treatment of the hepatic metastases,
- Previous 5FU +/- oxaliplatin-based adjuvant chemotherapy administered after colorectal tumor resection is authorized if complete more than 1 year before,
- Age ≥ 18 & ≤ 75 years
- Performance status : ECOG 0 or 1,
- Life expectancy ≥ 3 months,
- Hemoglobin ≥ 9 g/dl,
- Polynuclear neutrophiles ≥ 1500/mm3,
- Platelets ≥ 100 000 mm3,
- Creatinemia ≤ 135 µmol/l (1,35 mg/dl)
- Total bilirubin ≤ 1.25 times the Upper Limit of Normal (ULN).
- Hepatic enzymes ASAT and ALAT < 5 x ULN,
- Negative pregnancy test for women of child-bearing age,
- Information given to the patient and signed informed consent,
- Public Health insurance coverage.
- Non metastatic and/or non measurable disease according to the RECIST v1.1 criteria.
- Non-resectable primary tumor (e.g.: T4 tumors) or incomplete resection R2.
- History of intestinal inflammatory disease.
- Specific contraindication to any of the study treatments.
- Patient who have previously received anti-EGFr (e.g., cetuximab) or anti-VEGF monoclonal antibody treatment (e.g., bevacizumab) or treatment with irinotecan.
- History of cancer considered as not cured.
- Stroke/CVA or pulmonary embolism within 6 months before inclusion.
- Significant concomitant disease such as: coagulopathy, respiratory or cardiac congestive insufficiency, non-medically controlled/unstable angina pectoris, myocardial infarction within 6 months prior to study entry, arterial hypertension and uncontrolled arrhythmia, severe infections.
- Clinical neuropathy, grade ≥1.
- Patient already included in another therapeutic trial using an experimental molecule.
- Pregnant women or women who might become pregnant during the study or lactating women.
- Men or women who can procreate and who do not abide with the use of a contraceptive means.
- Persons kept in detention or incapable of giving consent
- Patient unwilling or unable to comply with the medical follow-up required by the trial because of geographic social or psychological reasons.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A1 : Folfiri + targeted therapy Folinic Acid Every 2 weeks : * irinotecan 180 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A1 : Folfiri + targeted therapy Irinotecan Every 2 weeks : * irinotecan 180 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A1 : Folfiri + targeted therapy Cetuximab Every 2 weeks : * irinotecan 180 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A1 : Folfiri + targeted therapy 5-FU Every 2 weeks : * irinotecan 180 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A1 : Folfiri + targeted therapy Bevacizumab Every 2 weeks : * irinotecan 180 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A2 : Folfox 4 + targeted therapy Oxaliplatin Every 2 weeks : * oxaliplatin 85 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A2 : Folfox 4 + targeted therapy Folinic Acid Every 2 weeks : * oxaliplatin 85 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A2 : Folfox 4 + targeted therapy 5-FU Every 2 weeks : * oxaliplatin 85 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A2 : Folfox 4 + targeted therapy Bevacizumab Every 2 weeks : * oxaliplatin 85 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm A2 : Folfox 4 + targeted therapy Cetuximab Every 2 weeks : * oxaliplatin 85 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1 And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm B : Folfirinox + targeted therapy Oxaliplatin Every 2 weeks : * oxaliplatin 85 mg/m² D1 * irinotecan 150 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered. And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm B : Folfirinox + targeted therapy Folinic Acid Every 2 weeks : * oxaliplatin 85 mg/m² D1 * irinotecan 150 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered. And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm B : Folfirinox + targeted therapy 5-FU Every 2 weeks : * oxaliplatin 85 mg/m² D1 * irinotecan 150 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered. And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm B : Folfirinox + targeted therapy Irinotecan Every 2 weeks : * oxaliplatin 85 mg/m² D1 * irinotecan 150 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered. And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm B : Folfirinox + targeted therapy Bevacizumab Every 2 weeks : * oxaliplatin 85 mg/m² D1 * irinotecan 150 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered. And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days. Arm B : Folfirinox + targeted therapy Cetuximab Every 2 weeks : * oxaliplatin 85 mg/m² D1 * irinotecan 150 mg/m² D1 * Folinic acid 400 mg/m² D1 * 5FU 400 mg/m² bolus * 5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered. And targeted therapy in function of Kras: * For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days * For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days.
- Primary Outcome Measures
Name Time Method The main objective is to compare resection rates (R0 or R1) for hepatic metastases at least 4-6 weeks after the end of chemotherapy Number of patients (%) with hepatic metastases R0 or R1 resection.
- Secondary Outcome Measures
Name Time Method The objective response rate (CR and PR) after 4 cycles of treatment after 8 weeks The objective response rate (CR and PR) will be evaluated by the investigator with RECIST v1.1 criteria after 4 cycles. Patients with symptoms suggestive of disease progression will have a tumoral evaluation when symptoms will occur
Complete remission rate (CR) 6 months after the last study treatment (hepatic surgery or last chemotherapy cycle) 6 months Number of patients (%) with complete remission (CR) at 6 months after the last study treatment (hepatic surgery or last chemotherapy cycle)
Specific resection rates R0/R1/R2 24 weeks Specific resection rates (%) R0/R1/R2 is the rate of patients with a R0, R1 or R2 resection.
Complete pathological response 24 weeks Number of patients with Complete pathological response, defined as the absence of tumoral residues after the last chemotherapy cycle. It will be evaluated on liver resection piece, based on total or complete tumor necrosis in all tumor nodules
Toxicity of treatment Every 2 weeks Tolerance of the treatment will be based on toxicities of evaluated products by clinical and biological measurements (NCIC/CTC (CTCAE V4) criteria, except for peripheral neuropathy toxicity (Lévi scale)
Post operatory complications after 4 weeks Each post operatory complications (Hemorrhage, fistula, insufficiency, heart failure,..) will be graduated using Dindo classification (2004)
Progression-free survival (PFS) 8 months Progression-free survival is defined as the time from randomization to progression (RECIST v1.1 criteria) or death. Patients alive without progression will be censored at the last follow-up.
Overall survival (OS) 14 months Overall survival is defined as the time from randomization to death any cause or last follow-up news for patients alive (censored data).
Trial Locations
- Locations (1)
Centre Val d'Aurelle
🇫🇷Montpellier, France